Steel Partners, an existing InMode shareholder, has made an unsolicited $16.75-per-share cash acquisition offer, challenging a competing CEO-led buyout proposal. The bid values InMode at roughly $500 million and represents a material premium to prior trading levels. InMode manufactures the Morpheus8 RF microneedling platform and Lumenis-derived laser systems—core revenue drivers for high-margin medspa workflows. A change in control could reshape device pricing, loyalty rebates, and service terms. Steel Partners' playbook typically involves operational efficiency and margin optimization, which may translate to tighter pricing for end-users or shifts in the rebate structure (similar to the Alle/Aspire dynamics in toxin and filler markets). The outcome will likely determine whether InMode remains an independent innovator or becomes part of a larger roll-up. Either path carries implications for practices that have built workflows around Morpheus8 or rely on InMode's service and upgrade cycles.
Steel Partners Bids $16.75/Share for InMode — What the Takeover Battle Means for Your Device Choices
A rival cash offer tops the CEO-led buyout, signaling consolidation pressure across the RF microneedling and energy-device market.
Steel Partners' bid at $16.75/share tops the CEO-led offer and signals consolidation pressure across energy-device manufacturers.
Source: original report ↗
Frequently asked questions
What is Steel Partners offering for InMode and how does it compare to the CEO-led bid?
Steel Partners is offering $16.75 per share in an all-cash deal, valuing InMode at approximately $500 million. This unsolicited bid tops the competing CEO-led buyout proposal and represents a material premium to InMode's prior trading levels, putting pressure on the existing deal.
Will the InMode takeover affect Morpheus8 pricing and device costs for medspa practices?
A change in control could reshape device pricing, loyalty rebates, and service terms. Steel Partners' typical playbook focuses on operational efficiency and margin optimization, which may translate to tighter pricing for end-users or shifts in rebate structures, similar to consolidation dynamics seen in the toxin and filler markets.
What devices does InMode make and why does this acquisition matter?
InMode manufactures the Morpheus8 RF microneedling platform and Lumenis-derived laser systems—both core revenue drivers for high-margin medspa workflows. These are foundational tools for many practices, making ownership changes directly relevant to service delivery and upgrade planning.
What happens to InMode if Steel Partners wins the bid?
If Steel Partners acquires InMode, the company would likely become part of a larger roll-up focused on operational efficiency and margin optimization. This could result in changes to pricing models, service terms, and the pace of innovation compared to remaining independent.
Should medspa owners be concerned about InMode's acquisition battle?
Yes—the outcome will determine whether InMode remains an independent innovator or becomes part of a larger consolidation play. Either path carries implications for practices that have built workflows around Morpheus8, including potential shifts in device pricing, rebates, service access, and upgrade cycles.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Seasoned Expat Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.